The scientific focus adapted
to express the optimum potential
of your molecule

Marketing:
Unparalleled vision in metabolic disorders and risk assessment expertise for post-marketing studies and drug repositioning.

HeartArteryMacrophageLiverMusclePancreasAdipose Tissue

Preclinical development:
In-house predictive models and tracer technologies enable the generation of Proof of Concept efficacy data for your drugs.

Discovery:
Screening and lead validation utilize a dedicated research platform which combine with our focused scientific vision.

Home > News > Physiogenex to present radiotracer-based hyperinsulinemic euglycemic clamp studies and diabetic nephropathy models at the WCIR 2018 in Los Angeles, CA, USA

News detail

Return to all news & events

11/29/2018 Physiogenex to present radiotracer-based hyperinsulinemic euglycemic clamp studies and diabetic nephropathy models at the WCIR 2018 in Los Angeles, CA, USA

Physiogenex will be presenting radiotracer-based hyperinsulinemic euglycemic clamp studies and diabetic nephropathy models at the World Congress of Insulin Resistance (WCIR) 2018, in Los Angeles, CA, USA, November 29th – December 1st, 2018.

The abstracts will be presented by Dr. François Briand, Director of Research and Business Development, during the poster session on Thursday, November 29th, 6:30pm-7:30pm.

The effects of dapagliflozin in animal models of diabetic nephropathy will be also presented during the oral abstract session on Friday, November the 30th, 6:30pm-8:00pm.

If you want to set an appointment during the WCIR 2018 with Dr. François Briand to discuss about your preclinical projects, please contact us !